


# The Brazilian Journal of INFECTIOUS DISEASES

[www.elsevier.com/locate/bjid](http://www.elsevier.com/locate/bjid)



## Letter to the Editor

### Raoultella ornithinolytica causing fatal sepsis



Dear Editor,

*Raoultella ornithinolytica*, an encapsulated Gram-negative bacterium, is a member of the Enterobacteriaceae family. It rarely causes invasive infections.<sup>1,2</sup> There are underlying conditions such as pathology of biliary system and malignancy in most cases. Although the majority can recover with adequate antibiotic therapy, some cases have a fatal outcome.<sup>2-4</sup> A patient from our country with diabetic foot with ensuing bacteremia had been reported.<sup>5</sup> That case was successfully treated by tigecycline.

A 37-year old male patient with relapsing acute lymphocytic leukemia (ALL) was admitted to the hematology department for chemotherapy. He had been diagnosed 1.5 year before and had a history of bone marrow transplantation in the previous year. At first day of FLAG (Fludarabine 30 mg/m<sup>2</sup>, cytosine arabinoside (Ara-C) 2 g/m<sup>2</sup>, granulocyte colony stimulating factor (G-CSF) 5 µg/kg/day) chemotherapy, febrile neutropenia developed and piperacillin-tazobactam 4.5 g intravenously (iv) every 6 h was started. Fever was under control in third day, but recurred after 12 days of treatment. Amphotericin-B 3 mg/kg/day was started with monitoring of galactomannan levels; based on the findings of high resolution computed tomography (HRCT) antibiotic therapy was switched to imipenem 500 mg iv every 6 h. Tigecycline 150 mg iv every 12 h was also added because of Gram-negative bacilli growth in subsequent three blood cultures. Despite that antibiotic modification, there was persistence of fever. Blood cultures grew Gram-negative bacilli, which were identified as "Raoultella ornithinolytica" by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker Biotyper) and confirmed by conventional biochemical tests. MICs of antibiotics were determined by BD Phoenix automated microbiological system (Becton Dickinson, Sparks, MD, USA). Amoxicillin-clavulanic acid 1 g PO every 8 h was then added to the regimen. Clinical response did not ensue and it was switched to ciprofloxacin 400 mg iv every 12 h according to the results of antibiotic sensitivity testing (Table 1). The patient

**Table 1 – Susceptibility profile of *Raoultella ornithinolytica*.**

Antibiotic	Minimum inhibitory concentration (MIC)	Susceptibility
Amikacin	≤8	S
Ampicillin-sulbactam	>16/8	R
Aztreonam	>16	R
Cefazolin	>8	R
Cefepime	>16	R
Cefoperazon-sulbactam	>32/8	R
Cefoxitin	>16	R
Ceftazidime	16	R
Ceftriaxone	>4	R
Ciprofloxacin	1	S
Ertapenem	>1	R
Gentamicin	≤2	S
Imipenem	>8	R
Levofloxacin	≤1	S
Meropenem	>8	R
Piperacillin-tazobactam	>64/4	R
Trimethoprim-sulfamethoxazole	>4/76	R

S, susceptible; R, resistant.

was transferred to the intensive care unit where he died one week later.

It should be kept in mind that *Raoultella ornithinolytica* can be the etiologic agent especially in patients with underlying conditions. One of the most important issues is the multidrug resistant profile of these bacteria. Ten to fourteen days of treatment with tigecycline, amoxicillin-clavulanic acid, levofloxacin, and cefmetazole are recommended in the literature.<sup>3-5</sup> However, all of these drugs may fail in some cases, such as the patient herein reported.

## Conflicts of interest

The authors declare no conflicts of interest.

## REFERENCES

1. Drancourt M, Bollet C, Carta A, Rousselier P. Phylogenetic analyses of *Klebsiella* species delineate *Klebsiella* and *Raoultella* gen. nov., with description of *Raoultella ornithinolytica* comb. nov., *Raoultella terrigena* comb. nov. and *Raoultella planticola* comb. nov. *Int J Syst Evol Microbiol.* 2001;51:925e32.
2. Morais VP, Daporta MT, Bao AF, Campello MG, Andres GQ. Enteric fever-like syndrome caused by *Raoultella ornithinolytica* (*Klebsiella ornithinolytica*). *J Clin Microbiol.* 2009;47:868e9.
3. Haruki Y, Hagiya H, Sakuma A, Murase T, Sugiyama T, Kondo S. Clinical characteristics of *Raoultella ornithinolytica* bacteremia: a case series and literature review. *J Infect Chemother.* 2014;20:589–91.
4. Hadano Y, Tsukahara M, Ito K, Suzuki J, Kawamura I, Kurai H. *Raoultella ornithinolytica* bacteremia in cancer patients: report of three cases. *Intern Med.* 2012;51:31935.
5. Solak Y, Gul EE, Atalay H, Genc N, Tonbul HZ. A rare human infection of *Raoultella ornithinolytica* in a diabetic foot lesion. *Ann Saudi Med.* 2011;31:93e4.

Selçuk Kaya<sup>a,\*</sup>, Gülcin Bayramoğlu<sup>b</sup>, Mehmet Sönmez<sup>c</sup>, İftihar Köksal<sup>a</sup>

<sup>a</sup> Karadeniz Technical University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Trabzon, Turkey

<sup>b</sup> Karadeniz Technical University, School of Medicine, Department of Medical Microbiology, Trabzon, Turkey

<sup>c</sup> Karadeniz Technical University, School of Medicine, Department of Hematology, Trabzon, Turkey

\* Corresponding author at: Karadeniz Technical University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, 61080 Trabzon, Turkey.

E-mail address: eselkaya@gmail.com (S. Kaya).

Received 24 December 2014

Accepted 30 December 2014

Available online 24 January 2015

<http://dx.doi.org/10.1016/j.bjid.2014.12.010>

1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.